SCHEMBL2521160

SCHEMBL2521160

O=C(O)C(CCO)(CCO)C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ARG2 P78540 2/20 0.35
ARG1 P05089 1/20 0.35
CAMK2A Q9UQM7 1/20 0.32
ALDH1A1 P00352 3/20 0.32
TSHR P16473 2/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22283924 0.83 ALDH1A1 (0.37) ARG2ARG1ALDH1A1TSHR
SCHEMBL17141402 0.83 ALDH1A1 (0.38) ALDH1A1TSHR
SCHEMBL14739494 0.79 ARG2 (0.45) ARG2ARG1CAMK2A
SCHEMBL810647 0.79 TET2 (0.31)
SCHEMBL7775190 0.77 FFAR1 (0.46) ARG2ARG1CAMK2AALDH1A1TSHR
SCHEMBL18748755 0.77 FFAR1 (0.46) ARG2ARG1CAMK2AALDH1A1TSHR
SCHEMBL5163591 0.73 ARG2 (0.35) ARG2ARG1CAMK2AALDH1A1TSHR
SCHEMBL2374038 0.73 ARG2 (0.35) ARG2ARG1CAMK2AALDH1A1TSHR
SCHEMBL723172 0.72 ALDH1A1 (0.35) ARG2ARG1ALDH1A1TSHRTP53
SCHEMBL4810549 0.71 LMNA (0.47) CAMK2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3918017-A1 BINDER FOR AN AQUEOUS COATING COMPOSITION Allnex Austria GmbH (AT) 2021-12-08 EP disclosed
EP-3712190-A1 BINDER FOR AN AQUEOUS COATING COMPOSITION ALLNEX AUSTRIA GmbH (AT) 2020-09-23 EP disclosed
WO-2020157228-A1 BINDER FOR AN AQUEOUS COATING COMPOSITION ALLNEX AUSTRIA GMBH (AT) 2020-08-06 WO disclosed
EP-3689986-A1 BINDER FOR AQUEOUS COATING COMPOSITIONS ALLNEX AUSTRIA GmbH (AT) 2020-08-05 EP disclosed
US-20110251158-A1 FULLERENE THERAPIES FOR INFLAMMATION AND INHIBITION OF BUILD-UP OF ARTERIAL PLAQUE LUNA INNOVATIONS INCORPORATED (US) 2011-10-13 US disclosed
US-5280072-A Solid pulverulent form BAYER AKTIENGESELLSCHAFT (DE) 1994-01-18 US disclosed
EP-0441527-A2 Stabilized polymer latex composition ICI AMERICAS INC. (US) 1991-08-14 EP disclosed
US-5011883-A Containing protective colloid and alkyd resin ICI AMERICAS INC. (US) 1991-04-30 US disclosed
US-4983491-A LITHOGRAPHIC PRINTING PLATES FUJI PHOTO FILM CO., LTD. 1991-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251158-A1 FULLERENE THERAPIES FOR INFLAMMATION AND INHIBITION OF BUILD-UP OF ARTERIAL PLAQUE IL1B, IL1A, CD68 ARG2 153/4885ARG1 96/4885CAMK2A 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.